000118204 001__ 118204 000118204 005__ 20240319081020.0 000118204 0247_ $$2doi$$a10.3390/biomedicines10051094 000118204 0248_ $$2sideral$$a129600 000118204 037__ $$aART-2022-129600 000118204 041__ $$aeng 000118204 100__ $$aLapuente, J. P. 000118204 245__ $$aEvaluation in a Cytokine Storm Model in Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells) 000118204 260__ $$c2022 000118204 5060_ $$aAccess copy available to the general public$$fUnrestricted 000118204 5203_ $$aOur research group has been developing a series of biological drugs produced by cocul-ture techniques with M2-polarized macrophages with different primary tissue cells and/or mesen-chymal stromal cells (MSC), generally from fat, to produce anti-inflammatory and anti-fibrotic ef-fects, avoiding the overexpression of pro-inflammatory cytokines by the innate immune system at a given time. One of these products is the drug PRS CK STORM, a medium conditioned by allogenic M2-polarized macrophages, from coculture, with those macrophages M2 with MSC from fat, whose composition, in vitro safety, and efficacy we studied. In the present work, we publish the results obtained in terms of safety (pharmacodynamics and pharmacokinetics) and efficacy of the intravenous application of this biological drug in a murine model of cytokine storm associated with severe infectious processes, including those associated with COVID-19. The results demonstrate the safety and high efficacy of PRS CK STORM as an intravenous drug to prevent and treat the cytokine storm associated with infectious processes, including COVID-19. 000118204 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B31-20R 000118204 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000118204 590__ $$a4.7$$b2022 000118204 592__ $$a0.897$$b2022 000118204 591__ $$aPHARMACOLOGY & PHARMACY$$b68 / 278 = 0.245$$c2022$$dQ1$$eT1 000118204 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1 000118204 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b92 / 285 = 0.323$$c2022$$dQ2$$eT1 000118204 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2022$$dQ2 000118204 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b54 / 136 = 0.397$$c2022$$dQ2$$eT2 000118204 594__ $$a3.7$$b2022 000118204 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000118204 700__ $$aGómez, G. 000118204 700__ $$aMarco-Brualla, J. 000118204 700__ $$aFernández, P. 000118204 700__ $$aDesportes, P. 000118204 700__ $$aSanz, J. 000118204 700__ $$aGarcía-Gil, M. 000118204 700__ $$aBermejo, F. 000118204 700__ $$aMartín, J. V. S. 000118204 700__ $$aAlgaba, A. 000118204 700__ $$aDe Gregorio, J. C. 000118204 700__ $$aLapuente, D. 000118204 700__ $$aDe Gregorio, A. 000118204 700__ $$aLapuente, B. 000118204 700__ $$aGómez, S. 000118204 700__ $$ade las Viñas Andrés, M. 000118204 700__ $$0(orcid)0000-0002-5175-8394$$aAnel Bernal, A.$$uUniversidad de Zaragoza 000118204 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole. 000118204 773__ $$g10, 5 (2022), 1094 [27 pp]$$tBiomedicines$$x2227-9059 000118204 8564_ $$s4301701$$uhttps://zaguan.unizar.es/record/118204/files/texto_completo.pdf$$yVersión publicada 000118204 8564_ $$s2911246$$uhttps://zaguan.unizar.es/record/118204/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000118204 909CO $$ooai:zaguan.unizar.es:118204$$particulos$$pdriver 000118204 951__ $$a2024-03-18-16:08:39 000118204 980__ $$aARTICLE